Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Common Equity (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Common Equity for 9 consecutive years, with $926.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 29.75% to $926.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $926.2 million, a 29.75% decrease, with the full-year FY2024 number at $1.2 billion, up 19.28% from a year prior.
  • Common Equity was $926.2 million for Q3 2025 at Denali Therapeutics, down from $1.0 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.5 billion in Q1 2024 to a low of $811.3 million in Q3 2022.
  • A 5-year average of $1.1 billion and a median of $1.0 billion in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 113.62% in 2021, then decreased 29.75% in 2025.
  • Denali Therapeutics' Common Equity stood at $962.3 million in 2021, then rose by 8.33% to $1.0 billion in 2022, then dropped by 1.1% to $1.0 billion in 2023, then increased by 19.28% to $1.2 billion in 2024, then fell by 24.68% to $926.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Common Equity are $926.2 million (Q3 2025), $1.0 billion (Q2 2025), and $1.1 billion (Q1 2025).